This editorial refers to 'Beneficial effects of SR33805 in failing myocardium' by Y. Ait Mou et al., pp. 412-419, this issue.
Heart failure (HF) is a major international public health problem that is becoming epidemic as the population ages. 1 Despite advances in treating HF in ambulatory patients, acute cardiac decompensation and failure remain associated with high rates of morbidity and death. 1 Acute and decompensated end-stage HF cause low cardiac output that can be treated with positive inotropic agents to increase myocardial contractility. 2 Conventional inotropic agents such as Recent clinical studies suggest the Ca 2+ sensitizer levosimendan may be useful for short-term inotropic support in various clinical settings. 7 On the basis of these encouraging results, there is considerable interest in developing novel therapeutic agents that increase myofilament Ca 2+ sensitivity to provide inotropic support in HF.
In this issue of Cardiovascular Research, Ait Mou et al. 8 evaluate the beneficial effects of SR33805, a novel Ca 2+ sensitizer, on in vivo and in vitro contractile properties of the failing heart. In a prior study in ventricular myocytes from non-failing hearts, they showed that SR33805 increased peak contractions but reduced the amplitudes of L-type Ca 2+ currents and Ca 2+ transients. 9 They showed that the mechanism underlying the positive inotropic effect of SR33805
was an increase in myofilament Ca 2+ sensitivity, in particular when cells were stretched. 9 This combination of actions suggests that SR33805 may be an especially effective inotropic agent in the failing heart, where myocytes are subject to stretch and where diastolic Ca 2+ levels are already high. 4 In the current study, Ait Mou et al. 8 evaluate the effects of SR33805
in the setting of heart disease. The author's ligate the left coronary artery in rats to produce a myocardial infarction, which leads to HF after 18 weeks. 10 They use echocardiography to show that an intra- 
